Multiple myeloma (MM) is a hematologic cancer characterized by clonal proliferation of plasma cells within the bone marrow. It is the most serious form of plasma cell dyscrasias, whose complications—hypercalcemia, renal failure, anemia, and lytic bone lesions—are severe and justify the therapeutic management. Imaging of bone lesions is a cardinal element in the diagnosis, staging, study of response to therapy, and prognostic evaluation of patients with MM. Historically, the skeletal radiographic workup (SRW), covering the entire axial skeleton, has been used to detect bone lesions. Over time, new imaging techniques that are more powerful than SRW have been evaluated. Low-dose and whole-body computed tomography (CT) supplants SRW for the detection of bone involvement, but is of limited value in assessing therapeutic response. Bone marrow MRI, initially studying the axial pelvic-spinal skeleton and more recently the whole body, is an attractive alternative. Beyond its non-irradiating character, its sensitivity for the detection of marrow damage, its capacity to evaluate the therapeutic response and its prognostic value has been demonstrated. This well-established technique has been incorporated into disease staging systems by many health systems and scientific authorities. Along with positron emission tomography (PET)-18 fluorodeoxyglucose CT, it constitutes the current imaging of choice for MM. This article illustrates the progress of the MRI technique over the past three decades and situates its role in the management of patients with MM.

1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology 2014; 15: e538–e548.

2. Ghobrial IM, Landgren O. How I treat smoldering multiple myeloma. Blood 2014; 124: 3380–3338.

3. Hameed A, Brady JJ, Dowling P, et al. Bone disease in multiple myeloma: Pathophysiology and management. Cancer Growth and Metastasis 2014; 7: 33–42.

4. Hillengass J, Fechtner K, Weber MA, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. Journal of Clinical Oncology 2010; 28: 1606–1610.

5. Moulopoulos LA, Gika D, Anagnostopoulos A, et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Annals of Oncology 2005; 16: 1824–1828.

6. Dimopoulos MA, Moulopoulos LA, Datseris I, et al. Imaging of myeloma bone disease-implications for staging, prognosis and follow-up. Acta Oncologica 2000; 39: 823–827.

7. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–854.

8. Greipp PR, Miguel JS, Durie BGM, et al. International staging system for multiple myeloma. Journal of Clinical Oncology 2005; 23: 3412–3420.

9. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood 2006; 108: 3992–3996.

10. Lecouvet FE, Vande Berg BC, Maldague BE, et al. Vertebral compression fractures in multiple myeloma. Part I. Distribution and appearance at MR imaging. Radiology 1997; 204: 195–199.

11. Dimopoulos MA, Hillengass J, Usmani S, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement. Journal of Clinical Oncology 2015; 33: 657–664.

12. Durie BGM. The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system. European Journal of Cancer 2006; 42: 1539–1543.

13. NICE guidelines. Myeloma: Diagnosis and management [Internet]. London: The National Institute for Health and Care Excellence (NICE); 2016. Available from: https://www.nice.org.uk/guidance/ng35/chapter/Recommendations.

14. Kyle RA. Multiple myeloma: Review of 869 cases. Mayo Clinic proceedings 1975; 50: 29–40.

15. Galson DL, Silbermann R, Roodman GD. Mechanisms of multiple myeloma bone disease. BoneKEy Reports 2012; 1: 135.

16. Silvestris F, Cafforio P, Calvani N, et al. Impaired osteoblastogenesis in myeloma bone disease: Role of upregulated apoptosis by cytokines and malignant plasma cells. British Journal of Haematology 2004; 126: 475–486.

17. Collins CD. Multiple myeloma. Cancer Imaging 2010; 10: 20–31.

18. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009; 23: 1545–1556.

19. Kyle RA, Schreiman JS, McLeod RA, et al. Computed tomography in diagnosis and management of multiple myeloma and its variants. Archives of Internal Medicine 1985; 145: 1451–1452.

20. Helms CA, Genant HK. Computed tomography in the early detection of skeletal involvement with multiple myeloma. JAMA 1982; 248: 2886–2887.

21. Princewill K, Kyere S, Awan O, et al. Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey. Cancer Investigation 2013; 31: 206–211.

22. Gleeson TG, Moriarty J, Shortt CP, et al. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole body MRI (WBMRI). Skeletal Radiology 2009; 38: 225–236.

23. Terpos E, Kleber M, Engelhardt M, et al. European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica 2015; 100: 1254–1266.

24. Hillengass J, Moulopoulos LA, Delorme S, et al. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: A study of the International Myeloma Working Group. Blood Cancer Journal 2017; 7: e599.

25. Ippolito D, Franzesi CT, Spiga S, et al. Diagnostic value of whole-body ultra-low dose computed tomography in comparison with spinal magnetic resonance imaging in the assessment of disease in multiple myeloma. British Journal of Haematology 2017; 177: 395–403.

26. Pianko MJ, Terpos E, Roodman GD, et al. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease. Clinical Cancer Research 2014; 20: 5888–5897.

27. Bailly C, Leforestier R, Jamet B, et al. PET Imaging for initial staging and therapy assessment in multiple myeloma patients. International Journal of Molecular Sciences 2017; 18.

28. Vande Berg BC, Malghem J, Lecouvet FE, et al. Magnetic resonance imaging of normal bone marrow. European Radiology 1998; 8: 1327–1334.

29. Daffner RH, Lupetin AR, Dash N, et al. MRI in the detection of malignant infiltration of bone marrow. American Journal of Roentgenology 1986; 146: 353–358.

30. Lafforgue P, Clairet D, Chagnaud C, et al. Aspects and role of spinal MRI in the assessment of solitary plasmacytoma and multiple myeloma. Apropos of 11 cases. Revue du Rhumatisme et des Maladies Osteo-articulaires 1992; 59: 317–326.

31. Libshitz HI, Malthouse SR, Cunningham D, et al. Multiple myeloma: Appearance at MR imaging. Radiology 1992; 182: 833–837.

32. Fruehwald FX, Tscholakoff D, Schwaighofer B, et al. Magnetic resonance imaging of the lower vertebral column in patients with multiple myeloma. Investigative Radiology 1988; 23: 193–199.

33. Moulopoulos LA, Varma DG, Dimopoulos MA, et al. Multiple myeloma: Spinal MR imaging in patients with untreated newly diagnosed disease. Radiology 1992; 185: 833–840.

34. Rahmouni A, Divine M, Mathieu D, et al. Detection of multiple myeloma involving the spine: Efficacy of fat-suppression and contrast-enhanced MR imaging. American Journal of Roentgenology 1993; 160: 1049–1052.

35. Van de Berg BC, Lecouvet FE, Michaux L, et al. Stage I multiple myeloma: Value of MR imaging of the bone marrow in the determination of prognosis. Radiology 1996; 201: 243–246.

36. Lecouvet FE, Vande Berg BC, Michaux L, et al. Stage III multiple myeloma: Clinical and prognostic value of spinal bone marrow MR imaging. Radiology 1998; 209: 653–660.

37. Stabler A, Baur A, Bartl R, et al. Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: Assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. American Journal of Roentgenology 1996; 167: 1029–1036.

38. Lecouvet FE, De Nayer P, Garbar C, et al. Treated plasma cell lesions of bone with MRI signs of response to treatment: Unexpected pathological findings. Skeletal radiology 1998; 27: 692–695.

39. Lecouvet FE, Vande Berg BC, Malghem J, et al. Diffusion-weighted MR imaging: Adjunct or alternative to T1-weighted MR imaging for prostate carcinoma bone metastases? Radiology 2009; 252: 624.

40. Lecouvet FE, Vande Berg BC, Malghem J, et al. Magnetic resonance and computed tomography imaging in multiple myeloma. Seminars in Musculoskeletal Radiology 2001; 5: 43–55.

41. Vande Berg BC, Lecouvet FE, Michaux L, et al. Magnetic resonance imaging of the bone marrow in hematological malignancies. European Radiology 1998; 8: 1335–1344.

42. Venkitaraman R, Sohaib SA, Barbachano Y, et al. Detection of occult spinal cord compression with magnetic resonance imaging of the spine. Clinical Oncology 2007; 19: 528–531.

43. Cuenod CA, Laredo JD, Chevret S, et al. Acute vertebral collapse due to osteoporosis or malignancy: Appearance on unenhanced and gadolinium-enhanced MR images. Radiology 1996; 199: 541–549.

44. Moulopoulos LA, Yoshimitsu K, Johnston DA, et al. MR prediction of benign and malignant vertebral compression fractures. Journal of Magnetic Resonance Imaging 1996; 6: 667–674.

45. Lecouvet FE, Vande Berg BC, Michaux L, et al. Development of vertebral fractures in patients with multiple myeloma: Does MRI enable recognition of vertebrae that will collapse? Journal of Computer Assisted Tomography 1998; 22: 430–436.

46. Messiou C, Giles S, Collins DJ, et al. Assessing response of myeloma bone disease with diffusion-weighted MRI. The British Journal of Radiology 2012; 85: e1198–e1203.

47. Giles SL, Messiou C, Collins DJ, et al. Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology 2014; 271: 785–794.

48. Merz M, Hielscher T, Wagner B, et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia 2014; 28: 1902–1908.

49. Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications. Journal of Clinical Oncology 2007; 25: 1121–1128.

50. Lecouvet FE, Malghem J, Michaux L, et al. Vertebral compression fractures in multiple myeloma. Part II. Assessment of fracture risk with MR imaging of spinal bone marrow. Radiology 1997; 204: 201–205.

51. Moulopoulos LA, Dimopoulos MA, Weber D, et al. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. Journal of Clinical Oncology 1993; 11: 1311–1315.

52. Lecouvet FE, Dechambre S, Malghem J, et al. Bone marrow transplantation in patients with multiple myeloma prognostic significance of MR imaging. American Journal of Roentgenology 2001; 176: 91–96.

53. Mosebach J, Shah S, Delorme S, et al. Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation. Haematologica 2018; 103: 336–343.

54. Lecouvet FE, Malghem J, Michaux L, et al. Skeletal survey in advanced multiple myeloma: Radiographic versus MR imaging survey. British Journal of Haematology 1999; 106: 35–39.

55. Bauerle T, Hillengass J, Fechtner K, et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: Importance of whole-body versus spinal MR imaging. Radiology 2009; 252: 477–485.

56. Ghanem N, Lohrmann C, Engelhardt M, et al. Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. European Radiology 2006; 16: 1005–1014.

57. Giles SL, Desouza NM, Collins DJ, et al. Assessing myeloma bone disease with whole-body diffusion-weighted imaging: Comparison with X-ray skeletal survey by region and relationship with laboratory estimates of disease burden. Clinical Radiology 2015; 70: 614–621.

58. Baur-Melnyk A, Buhmann S, Becker C, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. American Journal of Roentgenology 2008; 190: 1097–1104.

59. Dyrberg E, Hendel HW, Al-Farra G, et al. A prospective study comparing whole-body skeletal X-ray survey with 18F-FDG-PET/CT, 18F-NaF- PET/CT and whole-body MRI in the detection of bone lesions in multiple myeloma patients. Acta Radiologica Open 2017; 66(10): 2058460117738809.

60. Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: Results of the IMAJEM study. Journal of Clinical Oncology 2017; 35: 2911–2918.

61. Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007; 92: 50–55.

62. Sachpekidis C, Mosebach J, Freitag MT, et al. Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: Comparison of functional imaging modalities. American Journal of Nuclear Medicine and Molecular Imaging 2015; 5: 479–492.